Epstein-Barr virus–positive mucocutaneous ulcer arising in a post–hematopoietic cell transplant patient followed by polymorphic posttransplant lymphoproliferative disorder and cytomegalovirus colitis

Human Pathology

Volumn 59, Issue , 2017, Pages 147-151

  Satou, Akira ^a,b,c   Kohno, Akio ^c   Fukuyama, Ryuichi ^c   Elsayed, Ahmed Ali ^a,d   Nakamura, Shigeo ^a  

^a NAGOYA UNIVERSITY HOSPITAL   (Japan)

^b AICHI MEDICAL UNIVERSITY HOSPITAL   (Japan)

^c Welfare Federation of Agricultural Cooperatives   (Japan)

^d MANSOURA UNIVERSITY   (Egypt)

Author keywords

EBV+ mucocutaneous ulcer; EBV+ posttransplant lymphoproliferative disorder; Hematopoietic cell transplant; Immunodeficiency

Indexed keywords

ARABINOSIDE; BRENTUXIMAB VEDOTIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ETOPOSIDE; MELPHALAN; PREDNISOLONE; RITUXIMAB; STEROID; VINCRISTINE; IMMUNOSUPPRESSIVE AGENT; VIRUS RNA;

ADULT; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CASE REPORT; CLINICAL OUTCOME; COLITIS; CYTOMEGALOVIRUS INFECTION; DRUG MEGADOSE; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS POSITIVE MUCOCUTANEOUS ULCER; FEMALE; FOLLOW UP; GENE REARRANGEMENT; HISTOPATHOLOGY; HOSPITAL DISCHARGE; HUMAN; HUMAN TISSUE; IMMUNOCOMPROMISED PATIENT; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LARGE CELL LYMPHOMA; LYMPHADENOPATHY; MELENA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OUTPATIENT DEPARTMENT; POLYMERASE CHAIN REACTION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; REMISSION; TONGUE; TREATMENT FAILURE; ULCER; ADVERSE EFFECTS; BIOPSY; COLITIS, ULCERATIVE; CYTOMEGALOVIRUS INFECTIONS; DISEASE COURSE; EPSTEIN-BARR VIRUS INFECTIONS; FATALITY; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; ISOLATION AND PURIFICATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOPROLIFERATIVE DISORDERS; OPPORTUNISTIC INFECTIONS; RECURRENT DISEASE; TIME FACTOR; TONGUE DISEASES; VIROLOGY;

BIOPSY; COLITIS, ULCERATIVE; CYTOMEGALOVIRUS INFECTIONS; DISEASE PROGRESSION; EPSTEIN-BARR VIRUS INFECTIONS; FATAL OUTCOME; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; IN SITU HYBRIDIZATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOPROLIFERATIVE DISORDERS; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; POLYMERASE CHAIN REACTION; RECURRENCE; RNA, VIRAL; TIME FACTORS; TONGUE DISEASES; ULCER;

EID: 84998678879     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2016.08.001     Document Type: Article

References (15)

1. [1] Dojcinov, SD, Venkataraman, G, Raffeld, M, Pittaluga, S, Jaffe, ES, EBV positive mucocutaneous ulcer—a study of 26 cases associated with various sources of immunosuppression. Am J Surg Pathol 34 (2010), 405–417.
2. [2] Nelson, AA, Harrington, AM, Kroft, S, Dahar, MA, Hamadani, M, Dhakal, B, Presentation and management of post–allogeneic transplantation EBV-positive mucocutaneous ulcer. Bone Marrow Transplant 51 (2016), 300–302.
3. [3] Moran, NR, Webster, B, Lee, KM, et al. Epstein Barr virus–positive mucocutaneous ulcer of the colon associated Hodgkin lymphoma in Crohn's disease. World J Gastroenterol 21 (2015), 6072–6076.
4. [4] Asano, N, Suzuki, R, Kagami, Y, et al. Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. Am J Surg Pathol 29 (2005), 1284–1293.
5. [5] van Dongen, JJ, Langerak, AW, Bruggemann, M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia 17 (2003), 2257–2317.
6. [6] Hart, M, Thakral, B, Yohe, S, et al. EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder. Am J Surg Pathol 38 (2014), 1522–1529.
7. [7] Yamakawa, N, Fujimoto, M, Kawabata, D, et al. A clinical, pathological, and genetic characterization of methotrexate-associated lymphoproliferative disorders. J Rheumatol 41 (2014), 293–299.
8. [8] Sadasivam, N, Johnson, RJ, Owen, RG, Resolution of methotrexate-induced Epstein-Barr virus–associated mucocutaneous ulcer. Br J Haematol, 165, 2014, 584.
9. [9] Magalhaes, M, Ghorab, Z, Morneault, J, Akinfolarin, J, Bradley, G, Age-related Epstein-Barr virus–positive mucocutaneous ulcer: a case report. Clin Case Rep 3 (2015), 531–534.
10. [10] McGinness, JL, Spicknall, KE, Mutasim, DF, Azathioprine-induced EBV-positive mucocutaneous ulcer. J Cutan Pathol 39 (2012), 377–381.
11. [11] Hashizume, H, Uchiyama, I, Kawamura, T, Suda, T, Takigawa, M, Tokura, Y, Epstein-Barr virus–positive mucocutaneous ulcers as a manifestation of methotrexate-associated B-cell lymphoproliferative disorders. Acta Derm Venereol 92 (2012), 276–277.
12. [12] Yufu, Y, Kimura, M, Kawano, R, et al. Epstein-Barr virus–associated T cell lymphoproliferative disorder following autologous blood stem cell transplantation for relapsed Hodgkin's disease. Bone Marrow Transplant 26 (2000), 1339–1341.
13. [13] Izumiya, S, Ishida, M, Hodohara, K, Yoshida, T, Okabe, H, Epstein-Barr virus–associated lymphoproliferative disorder developed following autologous peripheral blood stem cell transplantation for relapsing Hodgkin's lymphoma. Oncol Lett 3 (2012), 1203–1206.
14. [14] Hauke, RJ, Greiner, TC, Smir, BN, et al. Epstein-Barr virus–associated lymphoproliferative disorder after autologous bone marrow transplantation: report of two cases. Bone Marrow Transplant 21 (1998), 1271–1274.
15. [15] Powell, JL, Bunin, NJ, Callahan, C, Aplenc, R, Griffin, G, Grupp, SA, An unexpectedly high incidence of Epstein-Barr virus lymphoproliferative disease after CD34+ selected autologous peripheral blood stem cell transplant in neuroblastoma. Bone Marrow Transplant 33 (2004), 651–657.